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Abstract
Background: There is wide debate among transplant centres regarding the indications for liver trans-
plantation (LT) in malignancy. We report a single-centre experience with simultaneous LT and total
pancreatectomy or pancreaticoduodenectomy.
Methods: We performed a retrospective review of a prospectively established database of patients who
underwent simultaneous LT and total pancreatectomy or pancreaticoduodenectomy. We analysed demo-
graphics, indications, approach and outcomes.
Results: Between 1991 and 2006, 11 patients (four male; median age 51 years) underwent simultaneous
LT and total pancreatectomy (n = 4) or pancreaticoduodenectomy (n = 7). Indications included metastatic
neuroendocrine tumour (n = 5), hepatocellular carcinoma (n = 2), metastatic periampullary adenocarci-
noma (n = 1), periampullary adenocarcinoma with end-stage liver disease (ESLD) (n = 2) and intraductal
papillary mucinous neoplasm with ESLD (n = 1). The three patients with ESLD had non-alcoholic steato-
hepatitis, primary sclerosing cholangitis or cryptogenic cirrhosis. Median postoperative length of stay was
31 days (21–110 days). Overall median survival was 101 months (95% confidence interval 70.6–131.4).
One-year survival was 91%, 2-year 90%, 5-year 67% and 10-year 33%. Postoperative complications
included: re-operation (n = 4); anastamotic leak (n = 2); abdominal abscess (n = 3), and organ rejection
(n = 1).
Conclusions: We report a series of pancreatectomy or pancreaticoduodenectomy and simultaneous LT
in patients with extensive malignancy or impending liver failure that prevented pancreatectomy. This
series provides evidence that combined pancreatic resection and LT can be a strategy in both radical
resections and cases with ESLD that would otherwise preclude operative intervention.
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Introduction
Liver transplantation (LT) is performed around the world for both
end-stage liver disease (ESLD) and malignancy. Although Starzl
envisioned a role for LT in primary hepatic malignancy not ame-
nable to conventional resection,1 recurrence rates and the scarce
supply of donor organs restrict transplantation to those for whom
there is believed to be maximal survival benefit. The indications
for transplantation for malignancy in the USA and Europe con-
tinue to be debated. Although there are current accepted criteria
for LT in hepatocellular carcinoma (HCC), the indications are not
well defined in extensive primary and secondary malignancy.
In 1993 Bismuth and colleagues published a study comparing
disease-free survival of LT vs. liver resection in HCC. Their results
showed equivalent overall survival whether treated with trans-
plantation or resection, but subgroup analysis revealed an 83%
disease-free 3-year survival after transplant in single and binodu-
lar tumours <3 cm in diameter.2 Although the United Network for
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Organ Sharing (UNOS) bases its criteria for LT in primary hepatic
malignancy on these data, large transplant centres have found
some success using broader criteria and have challenged these
guidelines.3,4 This push for more liberal transplantation criteria in
primary liver malignancy is a focus of debate among transplant
centres.
There is also considerable debate over the appropriate treat-
ment for metastatic disease that is not amenable to limited resec-
tion. Although most centres have reported generally poor results
with overall and disease-free survival after radical resection and
transplantation for metastatic tumours, some centres have
reported favourable results, suggesting that the potential for cure
or palliation is patient- and/or disease-specific.5–7 Cumulatively,
these studies show mixed results, but there have been efforts to
find prognostic factors for survival with regard to patient selec-
tion, primary disease process and operation. Recently, there has
been an accumulation in evidence of prolonged palliation and
cure in the slower-growing metastatic neuroendocrine tumours.
Multiple centres report survival rates of 50–90% at 5 years after
transplant, usually with significant palliation from tumour
burden and endocrine function.8–11 Various papers, including a
review by Pascher et al. in 2005, have reported single and multi-
centre studies of overall survival and disease-free survival after LT
for metastatic neuroendocrine tumour, and found that patients
aged <50 years, undergoing less extensive operations (i.e. sparing
the stomach and pancreas) and with favourable tumour biology
(Ki67 and E-Cadherin) may gain the greatest benefit.10,12,13
Although indications for LT in primary and secondary hepatic
malignancy are evolving, there is a continued need to report out-
comes in the management of specific tumours, as well as the
surgical management of a variety of tumours. Here we describe a
15-year experience at a single institution with pancreatectomy
or pancreaticoduodenectomy and simultaneous LT for multiple
diagnoses in order to better define how management may impact
survival.
Materials and methods
Approval for this study was obtained from our Institutional
Review Board. A search for simultaneous pancreatectomy or pan-
creaticoduodenectomy and LT was performed on a prospective
database for all patients who underwent transplantation at the
University of Pittsburgh between 1991 and 2006. We analysed
patient demographics, indications, operations, complications and
survival rates.
A series of 11 patients with the above criteria were found
(four pancreatectomy, seven pancreaticoduodenectomy). They
included seven females and four males, with a median age of 51
years (range 17–67 years). Primary diagnoses were neuroendo-
crine tumour (n = 5), periampullary adenocarcinoma (n = 3),
HCC (n = 2) and intraductal papillary mucinous neoplasm
(IPMN) (n = 1) (Table 1).
Results
Indications
All 11 patients undergoing pancreatectomy/
pancreaticoduodenectomy and LT had a malignant or pre-
malignant condition as the primary indication for operation.
Liver transplantation was undertaken for extensive primary liver
tumour (n = 2), malignancy metastatic to the liver (n = 6), or
localized non-hepatic malignancy in the setting of ESLD (n = 3).
Five patients had metastatic disease from a pancreatic neuroen-
docrine tumour and one patient had metastatic disease from a
pancreatic adenocarcinoma. Two patients had primary liver
malignancy (HCC) which extended into the duodenum. Three
patients had limited periampullary adenocarcinoma or IPMN
with pre-existing ESLD that met UNOS criteria for LT. In these
three patients the cause of ESLD included well-compensated
primary sclerosing cholangitis (PSC), decompensated non-
alcoholic steatohepatitis (NASH), and decompensated cryptoge-
Table 1 Patient demographics, including primary diagnosis and length of stay, for patients undergoing simultaneous pancreatectomy or
pancreaticoduodenectomy and liver transplantation
Patient Sex Age, years Postoperative LOS, days Primary tumour diagnosis
1 F 17 31 Duodenal carcinoid
2 F 60 25 IPMN
3 M 46 110 Periampullary adenocarcinoma
4 F 67 49 Periampullary adenocarcinoma
5 F 33 31 Neuroendocrine tumour
6 M 53 21 Neuroendocrine tumour
7 M 44 26 Neuroendocrine tumour
8 F 52 67 Neuroendocrine tumour
9 M 51 73 HCC
10 F 21 30 HCC (fibrolamellar)
11 F 52 33 Periampullary adenocarcinoma
LOS, length of stay; F, female; M, male; IPMN, intraductal papillary mucinous neoplasm; HCC, hepatocellular carcinoma
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nic cirrhosis with severe portal hypertension and failed
transjugular intrahepatic portosystemic shunt (TIPS).
Operations
In all patients, the extent of the disease was known prior to opera-
tion. All 11 patients in this series underwent pancreatectomy/
pancreaticoduodenectomy and cadaveric LT during the same
operation, although the order of resection and transplantation
varied. Five patients underwent only pancreaticoduodenectomy
and LT. Of these five, three had localized non-hepatic malignancy
with ESLD and underwent transplantation prior to pancreati-
coduodenectomy, one had duodenal carcinoid metastatic to the
liver and also underwent transplantation prior to pancreati-
coduodenectomy, and the remaining patient had HCC
with retroduodenal extension and underwent initial pancreati-
coduodenectomy immediately followed by LT.
The other six cases required more extensive resections, which
included colectomy and total pancreatectomy (Table 2). All of
them underwent resection prior to LT. Two patients had pan-
creaticoduodenectomy and colectomy for extensive HCC and
metastatic neuroendocrine tumour, respectively. Four others
underwent total pancreatectomy, three of them for metastatic
neuroendocrine tumour and one for extensive periampullary
adenocarcinoma.
It is of note that no patients received liver-directed chemo-
therapy or embolization prior to resection as this was not standard
practice at this institution at that time. In addition, patient records
showed no note of neoadjuvant or adjuvant chemotherapy.
Unfortunately, longterm follow-up data for degree of diabetes and
insulin requirements after pancreatectomy were not available in
these patients.
Complications
Four patients required re-operation. One patient required three
re-operations during the primary hospitalization for a pancreatic
anastamotic leak and subsequent abscesses and a second patient
underwent laparotomy for abscess drainage. Another patient in
the group underwent an exploratory laparotomy and ‘washout’
for suspected intra-abdominal sepsis. The final re-operative case
had two revisions of the pancreatic anastamosis and died on
hospital day 50 from multisystem organ failure. Non-operative
complications included one patient with thrombosis of the right
hepatic artery, one patient who suffered from graft vs. host
disease, and one with a postoperative myocardial infarction
(Table 2).
Survival
There was only one death during the initial hospitalization, and 10
of 11 patients lived for1 year. At the time of analysis, five of the
11 subjects were alive, with a median survival of 11 years (range
1–16 years). Overall median survival was 101 months (95% con-
fidence interval 70.6–131.4). One-year survival was 91%, 5-year
67% and 10-year 33% (Table 3).
Discussion
Liver transplantation inmalignancy is a highly controversial topic.
Because of the current limitations of available organs, the most
widely accepted practice is to follow guidelines which seemingly
optimize survival after transplantation. Recent studies of primary
and secondary hepatic malignancy have shown that important
criteria for prolonged survival or palliation include tumour type,
tumour biology, patient age and the extent of operation.
There is a general consensus that resection and transplantation
for neuroendocrine tumours may yield longterm palliation and
survival as a result of the slow-growing nature of these tumours.
Because of the relative success of surgical treatment of these
tumours, more extensive studies regarding the tumour biology
and patient factors associated with survival have been carried out.
Such studies have revealed that age, extent of operation and
molecular markers Ki67 and E-cadherin may be useful in predict-
ing survival.10,14 Additionally, there have been reports of success
Table 2 Operative procedures, postoperative complications and indications for re-operation
Patient Operation Complications Re-operation
1 Whipple + OLT Abscess 1 (abscess drainage)
2 Whipple + OLT Anastamotic leak No
3 Whipple + OLT Abscess; anastamotic leak 2 (abscess drainage ¥ 2)
4 Whipple + OLT Anastamotic disruption; death 3 (anastamotic revision ¥ 2; rule out abscess)
5 Pancreatectomy + duodenectomy + OLT GVHD No
6 Total panc + OLT None No
7 Total panc + OLT Thrombosed right hepatic artery No
8 Whipple + transverse colectomy + OLT Myocardial infarction No
9 Whipple + transverse colectomy + OLT None 1 (rule out abscess)
10 Whipple + OLT None No
11 Pancreatectomy + duodenectomy + OLT None No
OLT, orthotopic liver transplantation; GVHD, graft vs. host disease
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with radical resection in multiple types of cancer, but these are
few and have not been duplicated across multiple transplant
centres.6,7,15–17
Indications for LT are evolving, and it is of crucial importance
that centres accurately report their outcomes so that organ utili-
zation is optimized and perhaps indications expanded. Selection
criteria for type of tumour, extent of tumour and biological prop-
erties are changing, but there are limited reports on how the extent
of operation can impact survival.13,18 Most reports discuss ‘exten-
sive’ vs. ‘limited’ operations, which can vary frommultistage resec-
tion and transplantation to cluster resections and multivisceral
transplants. There are no studies specifically addressing simulta-
neous LT and pancreatectomy or pancreaticoduodenectomy in
cancer and/or ESLD.
Here, we report a series of 11 patients operated over a period of
16 years who underwent LT with simultaneous pancreatic opera-
tions for locally advanced malignancy or confined malignancy in
the setting of ESLD. We found only one in-hospital death and a
median post-transplant survival of 101 months. Our practice has
evolved over this period and the indications for radical resection
with LT have changed to accommodate better understanding of
tumour biology and advances such as directed chemoemboliza-
tion. In the early part of our series we found that the decision for
radical resection or transplantation was driven by attempts at
curative resection for a variety of malignancies that originated
from or spread to the liver in an era when the biology of disease
following transplantation was largely unknown. The later part of
our series demonstrates a shift towards performing transplanta-
tion or resection in patients with ESLD that would otherwise
preclude these patients from undergoing well established proce-
dures for their given pathology. Although these operations pre-
sented obvious technical challenges, we believe that our practice of
performing LT prior to oncological resection and ensuring that it
was accomplished with good preliminary function made a vital
contribution to their general success. No cases were approached
and abandoned as a result of complications with the LT.
Although this series does not allow us to derive prognostic
indicators for longterm survival, it does demonstrate that LT
combined with pancreaticoduodenectomy or pancreatectomy can
result in prolonged survival. Althoughmany of the studies that led
to the current standards in LT were small, retrospective series, they
have been crucial in determining how to best allocate organs that
are in scarce supply.
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